Involvement of nuclear steroid/thyroid/retinoid receptors and of protein kinases in the regulation of growth and of c-erbB and retinoic acid receptor expression in MCF-7 breast cancer cells

Breast Cancer Research and Treatment

Volumn 58, Issue 2, 1999, Pages 171-181

  Schneider, Sonja M ^a   Offterdinger, Martin ^a   Huber, Heinz ^a   Grunt, Thomas W ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; c erbB; Cross talk regulation; RAR; Retinoid; Steroid

Indexed keywords

ANTIESTROGEN; C ERB B RECEPTOR; CELL NUCLEUS RECEPTOR; COLECALCIFEROL; CYCLIC AMP DEPENDENT PROTEIN KINASE; DEXAMETHASONE; ESTRADIOL; ESTROGEN RECEPTOR; FORSKOLIN; FULVESTRANT; GLUCOCORTICOID RECEPTOR; LIOTHYRONINE; MEMBRANE RECEPTOR; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE; PROTEIN TYROSINE KINASE; RECEPTOR; RETINOIC ACID; RETINOIC ACID RECEPTOR; STEROID RECEPTOR; TAMOXIFEN; THYROID RECEPTOR; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVATION; EPITHELIUM CELL; FLOW CYTOMETRY; GROWTH REGULATION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; ONCOGENE C ERB; PRIORITY JOURNAL;

BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIVISION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; PROTEIN KINASES; RECEPTOR, ERBB-2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; TUMOR CELLS, CULTURED;

EID: 0033403558     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006377006816     Document Type: Article

References (52)

1. 1. Carraway KL III, Cantley LC: A neu acquaintance for erbB-3 and erbB-4: a role for receptor heterodimerization in growth signaling. Cell 78: 5-8, 1994
2. 2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
3. 3. Boccardo F, Canobbio L, Resasco M, Decensi AU, Pastorino G, Brema F: Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer. J Cancer Res Clin Oncol 116: 503-506, 1990
4. 4. Decensi A, Formelli F, Torrisi R, Costa A: Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints. J Cell Biochem Suppl 17G: 226-233, 1993
5. 5. Moon RC, Mehta RG, Detrisac CJ: Retinoids as chemo-preventive agents for breast cancer. Cancer Detect Prev 16: 73-79, 1992
6. 6. Durand B, Saunders M, Leroy P, Leid M, Chambon P: All-trans and 9-cis retinoic acid induction of CRABPII transcription is mediated by RAR-RXR heterodimers bound to DR1 and DR2 repeated motifs. Cell 71: 73-85, 1992
7. 7. Leid M, Kastner P, Lyons R, Nakshatri H, Saunders M, Zacharewski T, Chen J-Y, Staub A, Garner JM, Mader S, Chambon P: Purification, Cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 68: 377-395, 1992
8. 8. Nagaya T, Kopp P, Kitajima K, Jameson JL, Sco H: Second zinc finger mutants of thyroid hormone receptor selectively preserve DNA binding and heterodimerization but eliminate transcriptional activation. Biochem Biophys Res Commun 222: 524-530, 1996
9. 9. Schrader M, Bendik I, Becker-Andre M, Carlberg C: Interaction between retinoic acid and vitamin D signaling pathways. J Biol Chem 268: 17830-17836, 1993
10. 3-receptor/retinoid X receptor heterodimer binding to DNA. J Biol Chem 267: 23248-23252, 1992
11. 11. Yu VC, Delsert C, Andersen B, Holloway JM, Devary OV, Näär AM, Kim SY, Boutin JM, Glass CK, Rosenfield MG: RXRβ: a coregulator that enhances binding of retinoic acid, thyroid hormone and vitamin D receptors to their cognate response elements. Cell 67: 1251-1266, 1991
12. 12. Grunt T, Saceda M, Martin M, Lupu R, Dittrich E, Krupitza G, Harant H, Huber H, Dittnch C: Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer 63: 560-567, 1995
13. 13. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446, 1995
14. 14. Read LD, Keith D Jr, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947-3951, 1990
15. 15. Russell KS, Hung MC: Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res 52: 6624-6629, 1992
16. 16. Saceda M, Grunt TW, Colomer R, Lippman ME, Lupu R, Martin MB: Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. Endocrinology 137: 4322-4330, 1996
17. 17. Tang CK, Perez C, Grunt TW, Waibel C, Cho C, Lupu R: Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 56: 3350-3358, 1996
18. 18. Bacus SS, Kiguchi K, Chin D, King CR, Hubermann E: Differentiation of human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol Carcinog 3: 350-362, 1990
19. 19. Flicker S, Schneider SM, Offterdinger M, Dittrich E, Valenta R, Huber H, Dittrich C, Grunt TW: c-erbB receptor tyrosine kinase signaling pathways control the expression of retinoid/steroid receptors in breast cancer cells. Cancer Lett 115: 63-72, 1997
20. 20. Grunt TW, Dittrich E, Offterdinger M, Schneider SM, Dittrich C, Huber H: Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Brit J Cancer 78: 79-87, 1998
21. 21. Butler WB, Fontana JA: Responses to retinoic acid of tamoxifen-sensitive and -resistant sublines of human breast cancer cell line MCF-7. Cancer Res 52: 6164-6167, 1992
22. 22. Rishi AK, Shao ZM, Baumann RG, Li XS, Sheikh MS, Kimura S, Bashirelahi N, Fontana JA: Estradiol regulation of the human retinoic acid receptor alpha gene in human breast carcinoma cells is mediated via an imperfect half-palindromic estrogen response element and Sp1 motifs. Cancer Res 55: 4999-5006, 1995
23. 23. Roman SD, Ormandy CJ, Manning DL, Blamey RW, Nicholson RI, Sutherland RL, Clarke CL: Estradiol induction of retinoic acid receptors in human breast cancer cells. Cancer Res 53: 5940-5945, 1993
24. 24. Rubin M, Fenig E, Rosenauer A, Menendez-Botet C, Achkar C, Bentel JM, Yahalom J, Mendelsohn J, Miller WH Jr: 9-cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res 54: 6549-6556, 1994
25. 25. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA: High-titer HER 2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15: 3363-3367, 1997
26. 26. Fitzgerald P, Teng M, Chandraratna RA, Heyman RA, Allegretto EA: Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res 57: 2642-2650, 1997
27. 27. Fontana X, Ferrari P, Namer M, Peysson R, Salanon C, Bussiere F: C-erb-B2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis. Anticancer Res 14: 2099-2104, 1994
28. 28. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ: Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90: 37-42, 1998
29. 29. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D, Tang C: The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat 38: 57-66. 1996
30. 30. Pellegrini R, Mariotti A, Tagliabue E, Bressan R. Bunone G, Coradini D, Della Valle G, Formelli F, Cleris L, Radice P, Pierotti MA, Colnaghi MI, Ménard S: Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl)retinamide. Cell Growth Differ 6: 863-869, 1995
31. 31. Rock CL, Saxe GA, Ruffin MT 4th, August DA, Schottenfeld D: Carotenoids, vitamin A, and estrogen receptor status in breast cancer. Nutr Cancer 25: 281-296, 1996
32. 32. Stoll BA: Breast cancer: further metabolic-endocrine risk markers? Brit J Cancer 76: 1652-1654, 1997
33. 33. Harant H, Lindley I, Uthman A, Ballaun C, Krupitza G, Grunt T, Huber H, Dittrich C: Regulation of interleukin-8 gene expression by all-trans retinoic acid. Biochem Biophys Res Commun 210: 898-906, 1995
34. 3 in breast cancer cells occur at the estrogen response element level but through different molecular mechanisms. Cancer Res 54: 1458-1464, 1994
35. 35. Wu Q, Dawson MI, Zheng Y, Hobbs PD, Agadir A, Jong L, Li Y, Liu B, Zhang XK: Inhibition of trans-retinoic acid resistant human breast cancer cell growth by retinoid X receptor-selective retinoids. Mol Cell Biol 17: 6598-6608, 1997
36. 36. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW: Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 58: 478-484, 1998
37. 37. Bates NP, Hurst HC: An intron 1 enhancer element mediates oestrogen-induced suppression of erbB-2 expression. Oncogene 15: 473-181, 1997
38. 38. Dobashi K, Weiner DB, Greene MI: Differential regulation of oncogenic and cellular p185 by serine/threonine kinases. DNA 8: 723-732, 1989
39. 39. Taverna D, Antoniotti S, Maggiora P, Dati C, De Bortoli M, Hynes NE: erbB-2 expression in estrogen-receptor-positive breast-tumor cells is regulated by growth-modulatory reagents. Int J Cancer 56: 522-528, 1994
40. 40. Roman SD, Clarke CL, Hall RE, Alexander JE, Sutherland RL: Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res 52: 2236-2242, 1992
41. 41. Yen A, Roberson MS, Varvayanis S, Lee AT: Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 58: 3163-3172, 1998
42. 42. Rochette-Egly C, Oulad-Abdelghani M, Staub A, Pfister V, Scheuer I, Chambon P, Gaub MP: Phosphorylation of the retinoic acid receptor-alpha by protein kinase A. Mol Endocrinol 9: 860-871, 1995
43. 43. Rochette-Egly C, Adam S, Rossignol M, Egly JM, Chambon P: Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell 90: 97-107, 1997
44. 44. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harley E, Graupner G, Lu XP, Pfahl M: A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372: 107-111, 1994
45. 45. Schule R, Rangarajan P, Yang N, Kliewer S, Ransone U, Bolado J, Verma IM, Evans RM: Retinoic acid is a negative regulator of AP-1 responsive genes. Proc Natl Acad Sci USA 88: 6092-6096, 1991
46. 46. Martin MB, Garcia-Morales P, Stoica A, Solomon HB, Pierce M, Katz D, Zhang S, Danielsen M, Saceda M: Effects of 12-O-tetradecanoylphorbol-13-acetate on estrogen receptor activity in MCF-7 cells. J Biol Chem 270: 25244-25251, 1995
47. 47. De-Launoit Y, Kiss R: Influence of L-thyrexine, L-triiodothyronine, thyroid stimulating hormone, or estradiol on the cell kinetics of cultured mammary cancer cells. In Vitro Cell Dev Biol 25: 585-591, 1989
48. 48. Guilbaud NF, Gas N, Dupont MA, Valette A: Effects of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells. J Cell Physiol 145: 162-167, 1990
49. 49. Zhu WY, Jones CS, Kiss A, Matsukuma K, Amin S, De Luca LM: Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells. Exp Cell Res 234: 293-299, 1997
50. 50. De Vincenzo R, Scambia G, Benedetti-Panici P, Fattorossi A, Bonanno G, Ferlini C, Isola G, Pernisco S, Mancuso S: Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast cancer cells. Int J Cancer 68: 340-348, 1996
51. 51. Darbon JM, Valette A, Jozan S, Issandou M, Bayard F: Dissociation between protein kinase C content and biological responsiveness to phorbol esters in tumor promotersensitive (MCF-7) and resistant (Rph-4) cells. Biochem Pharmacol 40: 1785-1792, 1990
52. 52. Brunner N, Bronzen D, Vindelov LL, Rygaard K, Spang-Thomsen M, Lippman ME: Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res 49: 1515-1520, 1989